129 related articles for article (PubMed ID: 30904905)
1. The Bone Markers Sclerostin, Osteoprotegerin, and Bone-Specific Alkaline Phosphatase Are Related to Insulin Resistance in Children and Adolescents, Independent of Their Association with Growth and Obesity.
Stanik J; Kratzsch J; Landgraf K; Vogel M; Thiery J; Kiess W; Körner A
Horm Res Paediatr; 2019; 91(1):1-8. PubMed ID: 30904905
[TBL] [Abstract][Full Text] [Related]
2. Sclerostin and osteoprotegerin: new markers of chronic kidney disease mediated mineral and bone disease in children.
Guven S; Gokce I; Cicek N; Yaman A; Vatansever P; Alpay H
J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1383-1390. PubMed ID: 33068383
[TBL] [Abstract][Full Text] [Related]
3. Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase.
Fischer DC; Mischek A; Wolf S; Rahn A; Salweski B; Kundt G; Haffner D
Ann Clin Biochem; 2012 Nov; 49(Pt 6):546-53. PubMed ID: 22984195
[TBL] [Abstract][Full Text] [Related]
4. Circulating levels of dickkopf-1, osteoprotegerin and sclerostin are higher in old compared with young men and women and positively associated with whole-body bone mineral density in older adults.
Coulson J; Bagley L; Barnouin Y; Bradburn S; Butler-Browne G; Gapeyeva H; Hogrel JY; Maden-Wilkinson T; Maier AB; Meskers C; Murgatroyd C; Narici M; Pääsuke M; Sassano L; Sipilä S; Al-Shanti N; Stenroth L; Jones DA; McPhee JS
Osteoporos Int; 2017 Sep; 28(9):2683-2689. PubMed ID: 28585053
[TBL] [Abstract][Full Text] [Related]
5. Markers of bone metabolism are affected by renal function and growth hormone therapy in children with chronic kidney disease.
Doyon A; Fischer DC; Bayazit AK; Canpolat N; Duzova A; Sözeri B; Bacchetta J; Balat A; Büscher A; Candan C; Cakar N; Donmez O; Dusek J; Heckel M; Klaus G; Mir S; Özcelik G; Sever L; Shroff R; Vidal E; Wühl E; Gondan M; Melk A; Querfeld U; Haffner D; Schaefer F;
PLoS One; 2015; 10(2):e0113482. PubMed ID: 25659076
[TBL] [Abstract][Full Text] [Related]
6. Sclerostin and Insulin Resistance in Prediabetes: Evidence of a Cross Talk Between Bone and Glucose Metabolism.
Daniele G; Winnier D; Mari A; Bruder J; Fourcaudot M; Pengou Z; Tripathy D; Jenkinson C; Folli F
Diabetes Care; 2015 Aug; 38(8):1509-17. PubMed ID: 26084344
[TBL] [Abstract][Full Text] [Related]
7. Sclerostin and its association with insulin resistance in children and adolescents.
Wędrychowicz A; Sztefko K; Starzyk JB
Bone; 2019 Mar; 120():232-238. PubMed ID: 30055341
[TBL] [Abstract][Full Text] [Related]
8. The relationship between serum FGF-23 concentration and insulin resistance, prediabetes and dyslipidemia in obese children and adolescents.
Kutluturk Y; Akinci A; Ozerol IH; Yologlu S
J Pediatr Endocrinol Metab; 2019 Jul; 32(7):707-714. PubMed ID: 31211688
[TBL] [Abstract][Full Text] [Related]
9. Serum concentrations of sclerostin and bone turnover markers in children with cow's milk allergy.
Ambroszkiewicz J; Rowicka G; Chełchowska M; Gajewska J; Strucińska M; Laskowska-Klita T
Med Wieku Rozwoj; 2013; 17(3):246-52. PubMed ID: 24296448
[TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications.
Morena M; Jaussent I; Dupuy AM; Bargnoux AS; Kuster N; Chenine L; Leray-Moragues H; Klouche K; Vernhet H; Canaud B; Cristol JP
Nephrol Dial Transplant; 2015 Aug; 30(8):1345-56. PubMed ID: 25854266
[TBL] [Abstract][Full Text] [Related]
11. Osteoprotegerin increases parallel to insulin resistance in obese adolescents.
Kotanidou EP; Kotanidis CP; Giza S; Serbis A; Tsinopoulou VR; Karalazou P; Tzimagiorgis G; Galli-Tsinopoulou A
Endocr Res; 2019; 44(1-2):9-15. PubMed ID: 29877745
[TBL] [Abstract][Full Text] [Related]
12. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis.
Terpos E; Fragiadaki K; Konsta M; Bratengeier C; Papatheodorou A; Sfikakis PP
Clin Exp Rheumatol; 2011; 29(6):921-5. PubMed ID: 22032557
[TBL] [Abstract][Full Text] [Related]
13. Sclerostin distribution in children and adolescents with type 1 diabetes mellitus and correlation with bone metabolism and bone mineral density.
Tsentidis C; Gourgiotis D; Kossiva L; Marmarinos A; Doulgeraki A; Karavanaki K
Pediatr Diabetes; 2016 Jun; 17(4):289-99. PubMed ID: 26094958
[TBL] [Abstract][Full Text] [Related]
14. Higher levels of s-RANKL and osteoprotegerin in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast signaling and predisposition to lower bone mass: a multivariate cross-sectional analysis.
Tsentidis C; Gourgiotis D; Kossiva L; Doulgeraki A; Marmarinos A; Galli-Tsinopoulou A; Karavanaki K
Osteoporos Int; 2016 Apr; 27(4):1631-1643. PubMed ID: 26588909
[TBL] [Abstract][Full Text] [Related]
15. Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects.
Ashley DT; O'Sullivan EP; Davenport C; Devlin N; Crowley RK; McCaffrey N; Moyna NM; Smith D; O'Gorman DJ
Metabolism; 2011 Jul; 60(7):994-1000. PubMed ID: 21087777
[TBL] [Abstract][Full Text] [Related]
16. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients.
Ishimura E; Okuno S; Ichii M; Norimine K; Yamakawa T; Shoji S; Nishizawa Y; Inaba M
J Clin Endocrinol Metab; 2014 Nov; 99(11):4315-20. PubMed ID: 25093620
[TBL] [Abstract][Full Text] [Related]
17. Clearance of Sclerostin, Osteocalcin, Fibroblast Growth Factor 23, and Osteoprotegerin by Dialysis.
Carlson N; Mortensen OH; Axelsen M; Pedersen RS; Heaf JG
Blood Purif; 2017; 44(2):122-128. PubMed ID: 28554171
[TBL] [Abstract][Full Text] [Related]
18. Bariatric Roux-En-Y Gastric Bypass Surgery: Adipocyte Proteins Involved in Increased Bone Remodeling in Humans.
Biagioni MFG; Mendes AL; Nogueira CR; Leite CV; Gollino L; Mazeto GM
Obes Surg; 2017 Jul; 27(7):1789-1796. PubMed ID: 28091892
[TBL] [Abstract][Full Text] [Related]
19. Serum bone alkaline phosphatase isoenzyme levels in normal children and children with growth hormone (GH) deficiency: a potential marker for bone formation and response to GH therapy.
Tobiume H; Kanzaki S; Hida S; Ono T; Moriwake T; Yamauchi S; Tanaka H; Seino Y
J Clin Endocrinol Metab; 1997 Jul; 82(7):2056-61. PubMed ID: 9215272
[TBL] [Abstract][Full Text] [Related]
20. Proinsulin and the proinsulin/insulin ratio in overweight and obese children and adolescents: relation to clinical parameters, insulin resistance, and impaired glucose regulation.
von Berghes C; Brabant G; Biebermann H; Krude H; Wiegand S
Pediatr Diabetes; 2011 May; 12(3 Pt 2):242-9. PubMed ID: 21518412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
